Stantec Q1: Record Backlog and Margin Expansion Fuel Growth, But Premium Keeps Upside Capped

What happened

Stantec's Q1 2026 net revenue rose 9.1% to $1.7 billion, adjusted EBITDA margin improved 70 bps to 16.9%, and adjusted EPS grew 14.7% to $1.33, while contract backlog reached a record $9.0 billion, up 13.2% year-over-year. The results affirm robust demand across infrastructure, water, and AI data-center markets, and management reiterated its 2026 organic growth guidance of mid-to-high single digits. However, the stock has already re-rated near $94, approaching the DeepValue report's trim-above level of $115, offering limited room for multiple expansion. The adjusted EBITDA margin of 16.9% sits slightly below the 2025 guidance range of 17.2-17.5%, and while the record backlog provides good visibility, any slowdown in conversion or margin compression could trigger a de-rating from the current ~35x P/E. Overall, the operational execution confirms the secular thesis, but the premium valuation keeps the risk-reward balanced and favors patience.

Implication

The double-digit backlog growth and margin expansion reinforce Stantec's profile as a high-quality infrastructure compounder, supporting high-teens EPS growth into 2026. However, at ~$94-100, the stock already discounts a strong trajectory, limiting upside to the ~$117 base case and exposing investors to downside if organic growth slips or margin guidance is missed. The reaffirmed mid-to-high single digit organic growth outlook is consistent with the base case but provides no catalyst for upward revision. Investors should closely monitor backlog conversion and EBITDA margin trajectory over the next two quarters; sustained margins above 17% and organic growth at or above mid-single digits would justify the multiple, while any negative surprises would prompt de-rating. Therefore, the prudent approach is to wait for a more attractive entry below $90 or until further evidence of margin upside materializes.

Thesis delta

Q1 results modestly strengthen the bull case by delivering record backlog and margin improvement, aligning with the base case scenario from the DeepValue report. However, the stock has appreciated since the report's reference price of ~$98, moving closer to the trim zone and reducing expected returns. The key nuance is that the margin expansion, while positive, is slightly slower than the full-year 2025 guidance, warranting careful monitoring of cost controls and integration execution.